» Articles » PMID: 8611678

Flt3 Ligand Induces Proliferation of Quiescent Human Bone Marrow CD34+CD38- Cells and Maintains Progenitor Cells in Vitro

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 1996 May 1
PMID 8611678
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

Flt3 is a class III tyrosine kinase receptor expressed on primitive human and murine hematopoietic progenitor cells (HPC). In previous studies using stroma-free short term assays, Flt3 ligand (FL) has been shown to induce proliferation of HPC at proportions similar to or less than c-kit ligand (steel factor, SF). Using long term stromal cocultivation assays, we studied the effects of FL on proliferation and differentiation of a highly primitive and cytokine nonresponsive subpopulation of human HPC, CD34+cd38- cells. Cell Proliferation was significantly greater with FL than with SF, when used individually or in combinations with interleukin-3 (IL-3) and/or IL-6. The effect of FL was greater on bone marrow (BM) CD34+CD38- cells than the more cytokine responsive cord blood CD34+CD38- cells. Little or no effect was seen with FL on more mature CD34+CD38+ cells from either BM or cord blood. The frequency of colony-forming units (CFU) and high proliferative potential-colony forming cells (HPP-CFC) during early culture ( < or = 30 days) was increased by both SF and FL to similar levels. However, in the LTC-IC period (35 to 60 days) and extended long-term culture initiating cell (ELTC-IC) period ( > 60 days), the frequency of CFU and HPP-CFC was significantly greater in cultures containing FL than those without FL (P < .0025). Fluorescence-activated cell sorter analysis of cultures after 21 days showed a significantly higher percentage of cells remained CD34+ in the combination of FL, IL-3, IL-6, and SF (F/3/6/S) than in 3/6/S (0.78% +/- 0.52% v 0.21% +/- 0.29% respectively, mean +/- SD). Cloning efficiency of BM CD34+CD38- cells was significantly increased by the addition of FL to the combination of 3/6/S (mean 11.7% v 0.5%, P < .0001). These data show that FL is able to induce proliferation of CD34+CD38-cells that are nonresponsive to other early acting cytokines and to improve the maintenance of progenitors in vitro.

Citing Articles

BCG immunotherapy promotes tumor-derived T-cell activation through the FLT3/FLT3LG pathway in bladder cancer.

Zhang W, Yu L, Chang Z, Xiong H J Cancer. 2024; 15(3):623-631.

PMID: 38213738 PMC: 10777044. DOI: 10.7150/jca.90085.


IL3 Has a Detrimental Effect on Hematopoietic Stem Cell Self-Renewal in Transplantation Settings.

Tajer P, Cante-Barrett K, Naber B, Vloemans S, van Eggermond M, van der Hoorn M Int J Mol Sci. 2022; 23(21).

PMID: 36361533 PMC: 9655151. DOI: 10.3390/ijms232112736.


Midostaurin In Acute Myeloid Leukemia: An Evidence-Based Review And Patient Selection.

Abbas H, Alfayez M, Kadia T, Ravandi-Kashani F, Daver N Cancer Manag Res. 2019; 11:8817-8828.

PMID: 31632141 PMC: 6782026. DOI: 10.2147/CMAR.S177894.


A model of hematopoietic bone marrow apoptosis during growth factor deprivation in combination with a cytokine.

Mouser C, Antoniou E, Vassiliou E Theor Biol Med Model. 2018; 15(1):8.

PMID: 29925399 PMC: 6011349. DOI: 10.1186/s12976-018-0080-2.


A functional DC cross talk promotes human ILC homeostasis in humanized mice.

Lopez-Lastra S, Masse-Ranson G, Fiquet O, Darche S, Serafini N, Li Y Blood Adv. 2018; 1(10):601-614.

PMID: 29296702 PMC: 5728352. DOI: 10.1182/bloodadvances.2017004358.